New research on Alzheimer’s disease led by the University at Buffalo reveals strong evidence that clinical trials on drugs that appeared not to benefit patients with the disease should now be reanalyzed in light of discoveries about a human-specific gene that divides the population into a one-to-three ratio.
The research builds on previous work by the UB group. That work found that this gene, CHRFAM7A, which is unique to humans but isn’t present in everyone in its active form, can determine whether or not they will respond to three out of the four Alzheimer’s disease treatments approved by the Food and Drug Administration that…
